Dominik Escher

Dominik Escher is a co-founder and Executive Chairman of CDR-Life AG and a founding partner of Puros Bioventures. Previously, he was a founder and CEO of ESBATech AG, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 89 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g. Brolucizumab). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with a specialization in Management and Organization from the ETH of Zurich.